Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.34 |
| ▸ | LDLR | P01130 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGAV | P06756 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860075 | 0.96 | RORC (0.36) | RORCITGB3ITGAVITGA2B | |
| SCHEMBL6860119 | 0.95 | RORC (0.34) | RORCLDLRKDM4EALDH1A1ITGB3 | |
| SCHEMBL6854297 | 0.95 | JAK2 (0.34) | RORCLDLRKDM4EALDH1A1ITGB3 | |
| SCHEMBL6853816 | 0.92 | RORC (0.35) | RORCALDH1A1ITGB3ITGAVITGA2B | |
| SCHEMBL6860149 | 0.91 | RORC (0.35) | RORCALDH1A1ITGB3ITGAVITGA2B | |
| SCHEMBL6860138 | 0.87 | TP53 (0.39) | RORCALDH1A1ITGB3ITGAV | |
| SCHEMBL6860571 | 0.86 | RORC (0.40) | RORCITGB3ITGAVITGA2B | |
| SCHEMBL6860473 | 0.86 | GAA (0.38) | RORCLDLRKDM4EITGB3ITGAV | |
| SCHEMBL6853671 | 0.83 | RORC (0.36) | RORCALDH1A1ITGB3ITGAVITGA2B | |
| SCHEMBL6860800 | 0.82 | NPC1 (0.39) | RORCALDH1A1ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | claimed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | claimed |
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | RORC 1719/4885LDLR 559/4885KDM4E 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.